The stock of Alumis Inc (ALMS) has gone down by -19.57% for the week, with a -15.91% drop in the past month and a -26.48% drop in the past quarter. The volatility ratio for the week is 9.61%, and the volatility levels for the past 30 days are 7.02% for ALMS. The simple moving average for the past 20 days is -19.69% for ALMS’s stock, with a -20.52% simple moving average for the past 200 days.
Is It Worth Investing in Alumis Inc (NASDAQ: ALMS) Right Now?
Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALMS is 21.34M and currently, short sellers hold a 10.16% of that float. On November 15, 2024, ALMS’s average trading volume was 147.35K shares.
ALMS) stock’s latest price update
Alumis Inc (NASDAQ: ALMS) has experienced a decline in its stock price by -12.95 compared to its previous closing price of 10.81. However, the company has seen a fall of -19.57% in its stock price over the last five trading days. globenewswire.com reported 2024-11-13 that – Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, including global Phase 3 ONWARD clinical trials for ESK-001 in moderate-to-severe plaque psoriasis, Phase 2b clinical trial for ESK-001 in systemic lupus erythematosus (SLE) and Phase 1 clinical study for A-005 being developed for neuroinflammatory and neurodegenerative diseases – SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent achievements and upcoming milestones.
Analysts’ Opinion of ALMS
Many brokerage firms have already submitted their reports for ALMS stocks, with Robert W. Baird repeating the rating for ALMS by listing it as a “Outperform.” The predicted price for ALMS in the upcoming period, according to Robert W. Baird is $25 based on the research report published on October 31, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ALMS reach a price target of $30. The rating they have provided for ALMS stocks is “Buy” according to the report published on October 17th, 2024.
Morgan Stanley gave a rating of “Overweight” to ALMS, setting the target price at $36 in the report published on July 23rd of the current year.
ALMS Trading at -16.62% from the 50-Day Moving Average
After a stumble in the market that brought ALMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.45% of loss for the given period.
Volatility was left at 7.02%, however, over the last 30 days, the volatility rate increased by 9.61%, as shares sank -15.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.12% lower at present.
During the last 5 trading sessions, ALMS fell by -19.57%, in comparison to the 20-day moving average, which settled at $11.72. In addition, Alumis Inc saw -29.25% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALMS starting from Foresite Labs, LLC, who purchase 2,500,000 shares at the price of $16.00 back on Jul 01 ’24. After this action, Foresite Labs, LLC now owns 5,584,889 shares of Alumis Inc, valued at $40,000,000 using the latest closing price.
Foresite Capital Management V, the 10% Owner of Alumis Inc, purchase 2,500,000 shares at $16.00 during a trade that took place back on Jul 01 ’24, which means that Foresite Capital Management V, is holding 5,584,889 shares at $40,000,000 based on the most recent closing price.
Stock Fundamentals for ALMS
The total capital return value is set at -0.45.
Currently, EBITDA for the company is -156.89 million with net debt to EBITDA at 1.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.26.
Conclusion
To wrap up, the performance of Alumis Inc (ALMS) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
